EKF: EPS up 26% on flat revenue, with strong Life Sciences growth and robust H2 outlook
H1 2026 saw flat revenue at £25.0m, improved gross margin to 53%, and a 26% rise in EPS, supported by share buybacks. Point-of-Care is set for H2 growth, while Life Sciences and contract manufacturing delivered strong gains. FY26 is expected to meet market expectations.Original document: EKF Diagno…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.